Journal of Vaccines & Vaccination

Boehringer Animal Health Research and Development, Boehringer Ingelheim Animal Health USA, Inc. 2412 S Loop Dr, Ames, IA 50010, USA

Publications

• Research   
  Efficacy of Ingelvac PRRS® Modified Live Virus Vaccine against Heterologous Porcine Reproductive and Respiratory Syndrome Virus Challenges
  Author(s): Abby Patterson, Greg Haiwick, Joseph Hermann*, Brian Fergen, Kenneth Wakeland, Wayne Chittick and Reid Philips
  
  Porcine reproductive and respiratory syndrome (PRRS) is an infectious disease caused by the PRRS virus (PRRSV) and characterized by reproductive failure, respiratory disease and weight loss in swine. Two randomized, blinded vaccination-challenge studies evaluated the efficacy of Ingelvac PRRS® modified live virus (MLV) vaccine in protecting pigs from the virulent heterologous PRRSV isolates, restriction fragment length polymorphism (RFLP) 1-3-4 and 1-7-4. In separate challenge studies, pigs were vaccinated on Day 0 with Ingelvac PRRS MLV or placebo ‘challenge control’ and challenged on Day 28 with PRRSV 1-3-4 or 1-7-4. In the 1-3-4 challenge study, pigs vaccinated with Ingelvac PRRS MLV demonstrated significantly lower median viraemia (area-under-the-curve for Day 28–42 [AUC28–42]; P<0.0001) compared with unvaccinated contro.. View more»
  

  Abstract PDF